🔗 Share this article

As the US undertakes unprecedented revisions to its vaccination guidelines, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on coronavirus shots throughout the global health crisis and has concentrated on alleged fatalities following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Schedule

Public health authorities planned to unveil major changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US out of alignment with many the international standard with no evidence for benefit. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric immunization guidelines in the US so as to align more like Denmark, a society with universal health coverage and a citizenry approximately the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Doubts Over Expertise

Dr. Høeg has little discernible background in drug development, approval processes or management, which has been typical for former leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a large organization. She lacks background in drug approvals.”

Past commissioners of the center would “be deeply familiar with legal statutes and the research of drug development”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who led CBER have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the generic program authorizes thousands of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one have to be managed,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the position, which manages over 5,000 personnel. “It’s a massive leadership role, if you execute it properly,” Woodcock said.

Response and Controversial Initiatives

In response to questions about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a representative stated that the “concerns stem from flawed presumptions”.

“Her experience is consistent with the responsibilities of her position,” the representative said, noting the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's controversial priority voucher program, a contentious rapid therapy clearance system that allegedly worried her preceding directors. “How are these medications being selected for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Established Past Work on Vaccines

Regarding immunizations, Høeg has a more established, if problematic, past, critics have noted. She authored a research paper using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the current administration featured changing regulations for recently developed shots and halting “unnecessary” vaccines, she said following the vote on a audio program. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from obtaining COVID-19 vaccines.

“She is an all-around ideologue who begins with her conclusions and tailors the evidence to accommodate the data in a highly deceptive, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|